No Data
No Data
On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.Paragon will not conduct any new campaigns that
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Express News | Spyre Therapeutics Appoints Accomplished Biopharma Leader DR. Sandra Milligan to Its Board of Directors
Positive Outlook on Spyre Therapeutics' IBD Pipeline and Financial Stability
Spyre Therapeutics Is Maintained at Overweight by Wells Fargo
Spyre Therapeutics Is Maintained at Overweight by Wells Fargo
Express News | Spyre Therapeutics, Inc. : Wells Fargo Raises Target Price to $40 From $35
No Data
BelleWeather : GILD is down .03%, or two cents. Two pennies. That is not a remarkable fall.
71731595 BelleWeather: Remarkable
DudeThatsDerpy : Sheesh. The spelling errors in this article make it feel less reliable.